[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-437559-105":59,"doc-detail-437559-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","real-world-evaluation-of-ceftriaxone-related-safety-events-a-stewardship-call-to-action","Real-world evaluation of ceftriaxone-related safety events - a stewardship call to action","","A ceftriaxone safety alert triggered a hospital-system review of rapid response and cardiac arrest events linked to the timing of intravenous cephalosporin administrations. Despite broad ceftriaxone use, the study identified a low rate of significant ceftriaxone-related adverse events, with incidence similar to other intravenous cephalosporins. The work compares event frequency across ceftriaxone and non-ceftriaxone groups to inform antimicrobial stewardship and safety evaluation.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":35,"@type":76,"position":81},"https://docshare.wps.com/document/healthcare/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/real-world-evaluation-of-ceftriaxone-related-safety-events-a-stewardship-call-to-action/437559/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/real-world-evaluation-of-ceftriaxone-related-safety-events-a-stewardship-call-to-action/437559.png","ImageObject",300,407,{"name":92,"@type":93},"Jasmine","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-06","2026-09-29",true,{"@type":102,"interactionType":103,"userInteractionCount":34},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What safety concern prompted the review of ceftriaxone events?","Question",{"text":112,"@type":113},"A ceftriaxone safety alert led the authors to review rapid response and cardiac arrest events in relation to the timing of intravenous cephalosporin administrations across a large healthcare system.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How did the study compare ceftriaxone-related outcomes with other cephalosporins?",{"text":117,"@type":113},"The investigation quantified significant events within defined time windows after IV cephalosporin administration and compared event rates between ceftriaxone and non-ceftriaxone groups.",{"name":119,"@type":110,"acceptedAnswer":120},"What overall finding did the authors report about the rate of significant ceftriaxone-related adverse events?",{"text":121,"@type":113},"Despite high utilization, the study found a low rate of significant ceftriaxone-related adverse events, with an incidence similar to other intravenous cephalosporins.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},437559,1791151505,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":34,"category_name":35,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":34,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":81,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":39,"preview_page_count":4},2336478487870,"https://ap-avatar.wpscdn.com/davatar_085a072bc5b1113ac321206ff7593b45","Antimicrobial Stewardship & Healthcare Epidemiology (2026), 6, e7, 1–3 doi:10.1017/ash.2025.10258  \nConcise Communication  \nReal-world evaluation of ceftriaxone-related safety events: a stewardship call to action  \nKristen Paciullo PharmD1 , Sujit Suchindran MD, MPH2 , Leila S. Hojat MD, MS2 , Benjamin Albrecht PharmD1, Sarah B. Green PharmD1 , K. Ashley Jones PharmD1, Daniel J. Rogers PharmD1 , Trinh P. Vu PharmD1  and Lucy S. Witt MD, MPH, MSc2   \n1Pharmacy Department, Emory Healthcare, Atlanta, GA, USA and 2Division of Infectious Diseases, Department of Medicine, Emory University School of Medicine, Atlanta, GA, USA  \nAbstract  \nA ceftriaxone safety alert prompted a review of rapid response and cardiac arrest events in relation to the timing of intravenous cephalosporin administrations across a large health system. Despite high utilization, we found a low rate of significant ceftriaxone-related adverse events with a similar incidence as other intravenous cephalosporins.  \n(Received 17 October 2025; accepted 3 December 2025)  \nIntroduction  \nCeftriaxone is a third-generation cephalosporin recommended asan empiric therapy option in many clinical practice guidelines.1,2 Ceftriaxone is used extensively due to its broad spectrum of activity, favorable pharmacokinetics, ease of dosing, limited drugdrug interactions, and high tolerability. Adverse effects associated with ceftriaxone are generally mild to moderate, with most reported being gastrointestinal related.2 In January 2025, the Alabama Department of Public Health issued an alert after receiving reports of 11 cases of potential adverse effects associated with ceftriaxone.3 In February 2025, the Georgia Department of Public Health (GA DPH) issued a similar health alert with approximately 10 cases reported.4 In collaboration with health departments across the United States, the Centers for Disease Control and Prevention (CDC) started an investigation to identify and characterize serious adverse events associated with ceftriaxone exposure. Since no manufacturer or lot number has been associated with these events, and no causal link to ceftriaxone has been established, a comprehensive review of significant events occurring after intravenous (IV) cephalosporin use across the inpatient setting was performed at our multi-hospital healthcare system to (1) identify ceftriaxone-related safety events as recommended by GA DPH and the CDC and (2) to characterize the rates of ceftriaxone-related events compared to other cephalosporins.  \nCorresponding author: Kristen Paciullo; [Email:](Email: kristen.paciullo@emoryhealthcare.org)[ kristen.paciullo@emoryhealthcare.org](Email: kristen.paciullo@emoryhealthcare.org)[ ](Email: kristen.paciullo@emoryhealthcare.org)[Cite this article:](Cite this article: Paciullo K)[ Paciullo K](Cite this article: Paciullo K), [Suchindran S](Suchindran S), [Hojat LS](Hojat LS), et al. Real-world evaluation ofceftriaxone-related safety events: a stewardship call to action. Antimicrob Steward Healthc  \nEpidemiol 2026. doi: 10.1017/ash.2025.10258  \nMethods  \nAs part of the investigation, the CDC asked healthcare providers to report cases dating back to September 1, 2024, that met the following criteria: occurring within six hours after receipt of injectable ceftriaxone in a non-intensive care unit (ICU) setting that resulted in death or required cardiopulmonary resuscitation (CPR) and was not attributed by the provider(s) to a cause other than ceftriaxone administration.5 A documentation tool within the electronic health record (EHR), “Code Narrator” was utilized to retrospectively identify significant events occurring within four hours after administration of an IV cephalosporin (cefazolin, cefuroxime, ceftriaxone, ceftazidime, cefepime) from October 1, 2022, to June 30, 2025, across our healthcare system comprising seven hospitals located in urban and suburban settings in Georgia. Code Narrator identifies rapid response events; those where a dedicated team respo","cbCaivdkI0iaaVvL","https://ap.wps.com/l/cbCaivdkI0iaaVvL","pdf",238102,"English","# Abstract\n# Introduction\n# Methods","[{\"question\":\"What safety concern prompted the review of ceftriaxone events?\",\"answer\":\"A ceftriaxone safety alert led the authors to review rapid response and cardiac arrest events in relation to the timing of intravenous cephalosporin administrations across a large healthcare system.\"},{\"question\":\"How did the study compare ceftriaxone-related outcomes with other cephalosporins?\",\"answer\":\"The investigation quantified significant events within defined time windows after IV cephalosporin administration and compared event rates between ceftriaxone and non-ceftriaxone groups.\"},{\"question\":\"What overall finding did the authors report about the rate of significant ceftriaxone-related adverse events?\",\"answer\":\"Despite high utilization, the study found a low rate of significant ceftriaxone-related adverse events, with an incidence similar to other intravenous cephalosporins.\"}]","Real-world evaluation of ceftriaxone-related safety events - a stewardship call to action | PDF",1790682373]